MCX share: UBS maintains buy with Rs 10,000 target, bullish on product pipeline and retail traction
UBS has reaffirmed its 'Buy' rating on Multi Commodity Exchange (MCX) with a target price of ₹10,000, citing strong growth catalysts from new product launches, rising retail participation, and strategic focus on liquidity enhancement. The stock is currently trading at ₹7,983, offering significant upside potential. UBS highlights key growth drivers for MCX
UBS identified three major takeaways from the recent investor call. First, MCX is focused on expanding its product portfolio, particularly with cash-settled index options, which are expected to attract higher participation. Second, there is a notable increase in retail activity, especially in popular bullion contracts like Gold Ten, indicating rising market depth. Third, MCX is actively pursuing initiatives to improve liquidity in electricity derivatives, including incentive-driven schemes aimed at broader participation. MCX stock split and valuation outlook
The company's board has also approved a stock split in a 1:5 ratio, which is expected to improve accessibility and trading volumes among retail investors. UBS believes the combination of product innovation, retail momentum, and market development initiatives positions MCX strongly for long-term growth.
Brokerage view summary: Brokerage Rating Target Price Key Takeaways UBS Buy ₹10,000 Positive on index options, retail in bullion, and electricity derivatives liquidity push
Disclaimer: This article is based on brokerage reports and is for informational purposes only. It does not constitute investment advice. Investors should consult their financial advisors before making investment decisions.
Ahmedabad Plane Crash
Arunika Jain, a graduate in Mass Communication, brings a fresh perspective to the world of journalism. Arunika has a passion for writing finance and corporate news at BusinessUpturn.com. You can write to her at [email protected]
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 hours ago
- Yahoo
UBS Affirms Elevance Health's (ELV) ‘Buy' Rating on Earning Stability and Growth Prospects
Elevance Health, Inc. (NYSE:ELV) is one of the best depressed stocks to buy in 2025. On July 28, UBS reiterated a 'Buy' rating on the stock and a $435 price target. The positive stance follows the healthcare company's second-quarter results. 15 States with the Best Healthcare in the US The healthcare company delivered adjusted earnings per share of $8.84, in line with consensus estimates. It also delivered $49.8 billion in revenues, beating expectations by 2.8%. Nevertheless, the company reduced its earnings per share outlook by $4.50, resulting in a $1.3 billion decrease in pretax income. Elevance also increased its 2025 medical loss ratio expectations by 90 basis points. Elevance attributes the higher medical loss expectations to worse-than-expected cost trends in the Affordable Care Act exchange and Medicaid businesses. UBS maintains a Buy rating on the stock, citing potential earnings stability and growth in the commercial and Carelon segments. Elevance Health, Inc. (NYSE:ELV) is a healthcare company dedicated to enhancing the health of individuals and communities. It offers a range of services, including health plans, clinical solutions, behavioral health, pharmacy benefits, and complex care solutions. While we acknowledge the potential of ELV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Top 10 Medical AI Companies to Buy According to Analysts and . Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Business Insider
10 hours ago
- Business Insider
UBS Keeps Their Hold Rating on Shopify (SHOP)
In a report released yesterday, Timothy Chiodo from UBS maintained a Hold rating on Shopify, with a price target of $145.00. The company's shares closed today at $149.61. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Chiodo covers the Technology sector, focusing on stocks such as Fiserv, Shopify, and Toast Inc. According to TipRanks, Chiodo has an average return of 6.3% and a 51.64% success rate on recommended stocks. In addition to UBS, Shopify also received a Hold from Truist Financial's Terry Tillman in a report issued today. However, yesterday, KeyBanc maintained a Buy rating on Shopify (NASDAQ: SHOP). The company has a one-year high of $156.85 and a one-year low of $65.86. Currently, Shopify has an average volume of 10.72M. Based on the recent corporate insider activity of 221 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SHOP in relation to earlier this year.
Business Insider
14 hours ago
- Business Insider
UBS Sticks to Their Hold Rating for Cf Industries Holdings (CF)
UBS analyst Joshua Spector maintained a Hold rating on Cf Industries Holdings yesterday and set a price target of $101.00. The company's shares closed today at $80.88. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. According to TipRanks, Spector is a 2-star analyst with an average return of -0.1% and a 49.25% success rate. Spector covers the Basic Materials sector, focusing on stocks such as Eastman Chemical, Methanex, and TRONOX. In addition to UBS, Cf Industries Holdings also received a Hold from Oppenheimer's Kristen Owen in a report issued yesterday. However, today, TR | OpenAI – 4o reiterated a Buy rating on Cf Industries Holdings (NYSE: CF). CF market cap is currently $14.56B and has a P/E ratio of 11.75. Based on the recent corporate insider activity of 71 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CF in relation to earlier this year. Most recently, in June 2025, Bert Frost, the EVP,Sales,MktDev&Supply Chain of CF sold 5,000.00 shares for a total of $503,500.00.
